Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | LPL | P06858 | 12/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5818521 | 0.98 | HIF1A (0.51) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL3708268 | 0.96 | LPL (0.49) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL16112310 | 0.93 | LPL (0.52) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL14804365 | 0.93 | LPL (0.52) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL2018524 | 0.86 | LPL (0.46) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL20428742 | 0.86 | ESR2 (0.49) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL14804355 | 0.86 | LPL (0.49) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL31222936 | 0.85 | SLC18A3 (0.51) | HIF1ALPLLIPG | |
| SCHEMBL16394142 | 0.85 | ESR2 (0.49) | HIF1ALPLLIPGCA1CA2 | |
| SCHEMBL16669514 | 0.85 | ESR2 (0.49) | HIF1ALPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4065230-A1 | THERAPEUTIC COMPOUNDS | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-108341774-B | Substituted quinolinone inhibitors | 首药控股(北京)股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2021108483-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1706395-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | HIF1A 813/4885LPL 4868/4885LIPG 4794/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | HIF1A 4280/4885LPL 3073/4885LIPG 4207/4885 |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | HIF1A 2751/4885LPL 3536/4885LIPG 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.